Synthesis and Screening of Some Novel Thiazole, Bithiazole and Thiazolidin-4-One Compounds with Biological Activity

Dear Colleagues,

It is a great pleasure and honor for us to invite you to contribute to the Special Issue entitled “Synthesis and Screening of Some Novel Thiazole, Bithiazole, and Thiazolidin-4-One Compounds with Biological Activity”.

Nitrogen- and sulfur-containing heterocycles represent a highly important class of compounds that are widespread in medicinal chemistry, receiving special attention in drug discovery.

Thiazole is one of the most important scaffolds in heterocyclic chemistry and drug design and discovery. It is widely found in diverse pharmacologically active substances and in some naturally-occurring compounds. Thiazole is a versatile building-block for lead generation and provides easy access to diverse derivatives for subsequent lead optimization. In recent years, many thiazole derivatives, including bithiazole, have been synthesized and subjected to varied biological activities, such as antibacterial, antifungal, anti-HIV, anti-inflammatory, antiparasitic, antitubercular, and antitumor activity. Some drugs that already are on the market (e.g., Dasatinib, Sulfathiazole, Bleomycin, Ritonavir, Meloxicam, etc.) possess a thiazole nucleus.

4-thiazolidinones also present a variety of chemical properties and biological activities, such as anticancer, antiviral, anticonvulsant, cardiovascular, antiinflammatory, analgesic, antidiabetic, antihyperlipidemic, antibacterial, antituberculosis, and antiparasitic, among others. Some 4-thiazolidinone derivatives, such as Etozoline (diuretic), are now on the pharmaceutical market.

Moreover, these scaffolds also have applications as fungicides, herbicides, agrochemicals, and antioxidants and play an important role in biochemical processes because they are key elements of some coenzymes.

Despite the extensive literature on N,S-heterocycles synthesis, there is great interest in the development of more innovative and efficient synthetic methodologies to obtain new chemical entities.

This Special Issue will accept original research papers and high-quality reviews in the fields of medicinal chemistry, organic chemistry, coordinating chemistry, biochemistry, and pharmacology. The topic of this Special Issue will be focused on drug design and development, new synthetic approaches, biosynthesis, isolation, and biological activity of new thiazole/bisthiazole and thiazolidin-4-one derivatives.

Prof. Dr. Brindusa Tiperciuc
Dr. Cristina Nastasa
Dr. Ioana Ionuț
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.